A native antigen "reverse capture" microarray platform for autoantibody profiling of prostate cancer sera

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Cancerous sera contain autoantibodies targeting autologous cellular antigens.
• Distinguishing prostate cancer from benign prostate hyperplasia (BPH) is clinically significant.
• Current diagnostic methods may require further refinement for accurate differentiation.

Purpose of the Study:

• To develop and validate a novel native antigen-based platform for identifying autoantigens.
• To assess the potential of autoantibody expression profiles in differentiating prostate cancer from BPH.
• To identify specific autoantigens that can serve as biomarkers for prostate cancer detection.

Main Methods:

• Utilized a "reverse capture" autoantibody microarray platform.
• Purified and differentially labeled IgG from prostate cancer and BPH patient sera.
• Performed competitive hybridization experiments with dye-swapping for robust data acquisition.

Main Results:

• Identified 28 unique antigen-autoantibody reactivities with potential to discriminate prostate cancer from BPH (p-value ≤0.01).
• Identified autoantigens fall into categories including protein kinases, cell-cycle regulators, and apoptosis mediators.
• Only one autoantigen remained differentially targeted post-surgery, suggesting specificity for active disease.

Conclusions:

• Autoantibody profiling using the reverse capture microarray platform shows promise for differentiating malignant from benign prostate diseases.
• The identified autoantigens represent potential novel biomarkers for prostate cancer diagnosis.
• This platform offers a sensitive approach for biomarker discovery in complex diseases.